Epidermal growth factor receptor inhibitors in lung cancer: Smaller or larger molecules, selected or unselected populations?

被引：23

作者：

Hirsch, FR ^{[1
]}

Bunn, PA ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 36期

关键词：

D O I：

10.1200/JCO.2005.03.6129

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9044 / 9047

页数：4

共 17 条

[1]

[Anonymous], [No title captured]

[2]

BAILEY LR, 2003, 94 ANN M AM ASS CANC

[3] Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J].

Cappuzzo, F ;

Gregorc, V ;

Rossi, E ;

Cancellieri, A ;

Magrini, E ;

Paties, CT ;

Ceresoli, G ;

Lombardo, L ;

Bartolini, S ;

Calandri, C ;

De Rosa, M ;

Villa, E ;

Crinò, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2658-2663

[4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[5] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC) [J].

Hanna, N ;

Bonomi, P ;

Lynch, T ;

Ansari, R ;

Govindan, R ;

Janne, R ;

Lilenbaum, R .

LUNG CANCER, 2005, 49 :S38-S38

[6] FISH and immunhistochemistry (IHC) can be used to select NSCLC patients, who will not benefit from Gefitinib treatment [J].

Hirsch, F ;

McCoy, J ;

Cappuzzo, F ;

Howard, W ;

Gumerlock, P ;

Crino, L ;

Franklin, W ;

Gandara, D ;

Varella-Garcia, M ;

Bunn, P .

LUNG CANCER, 2005, 49 :S38-S38

[7] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study [J].

Hirsch, FR ;

Varella-Garcia, M ;

McCoy, J ;

West, H ;

Xavier, AC ;

Gumerlock, P ;

Bunn, PA ;

Franklin, WA ;

Crowley, J ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6838-6845

[8]

KELLY K, 2003, P AN M AM SOC CLIN, V22, P644

[9]

KIM ES, 2003, P AN M AM SOC CLIN, V22, P642

[10] Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations [J].

Mukohara, T ;

Engelman, JA ;

Hanna, NH ;

Yeap, BY ;

Kobayashi, S ;

Lindeman, N ;

Halmos, B ;

Pearlberg, J ;

Tsuchihashi, Z ;

Cantley, LC ;

Tenen, DG ;

Johnson, BE ;

Jänne, PA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1185-1194

← 1 2 →